CBFB and acute myeloid leukemia: In de novo AML, a number of disease-related or even AML-specific driver mutations, such as RUNX1-RUNX1T1 (CBFB-MYH11), PML-RARa, FLT3 mutations, KIT D816V, or NPM1 mutations, have been identified [37,88,89,90,91,92].